Kim KA - Search Results

1

Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes.

Park JY, Kim KA, Kim SL. Park JY, et al. Among authors: kim ka, kim sl. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9. doi: 10.1128/AAC.47.11.3464-3469.2003. Antimicrob Agents Chemother. 2003. PMID: 14576103 Free PMC article.

2

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.

Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG. Shon JH, et al. Among authors: kim ka. Pharmacogenetics. 2002 Mar;12(2):111-9. doi: 10.1097/00008571-200203000-00005. Pharmacogenetics. 2002. PMID: 11875365 Clinical Trial.

3

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG. Kim KA, et al. Among authors: kim mj, kim mk. Clin Pharmacol Ther. 2002 Jul;72(1):90-9. doi: 10.1067/mcp.2002.126176. Clin Pharmacol Ther. 2002. PMID: 12152007 Clinical Trial.

4

Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes.

Park JY, Kim KA. Park JY, et al. Among authors: kim ka. Eur J Clin Pharmacol. 2003 Sep;59(5-6):407-9. doi: 10.1007/s00228-003-0641-z. Epub 2003 Aug 5. Eur J Clin Pharmacol. 2003. PMID: 12904931

5

Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.

Kim KA, Park JY. Kim KA, et al. Drug Metab Dispos. 2003 Sep;31(9):1090-2. doi: 10.1124/dmd.31.9.1090. Drug Metab Dispos. 2003. PMID: 12920163

6

Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes.

Kim KA, Park JY, Lee JS, Lim S. Kim KA, et al. Arch Pharm Res. 2003 Aug;26(8):631-7. doi: 10.1007/BF02976712. Arch Pharm Res. 2003. PMID: 12967198

7

Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.

Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. Kim KA, et al. Among authors: kim mj. Drug Metab Dispos. 2003 Oct;31(10):1227-34. doi: 10.1124/dmd.31.10.1227. Drug Metab Dispos. 2003. PMID: 12975331

8

Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.

Park JY, Kim KA, Park PW, Park CW, Shin JG. Park JY, et al. Among authors: kim ka. Clin Pharmacol Ther. 2003 Oct;74(4):334-40. doi: 10.1016/S0009-9236(03)00221-2. Clin Pharmacol Ther. 2003. PMID: 14534520 Clinical Trial.

9

Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.

Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Park JY, et al. Among authors: kim ka, kim sl. Clin Pharmacol Ther. 2004 Mar;75(3):157-62. doi: 10.1016/j.clpt.2003.10.003. Clin Pharmacol Ther. 2004. PMID: 15001966 Clinical Trial.

10

Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.

Kim KA, Lee JS, Park HJ, Kim JW, Kim CJ, Shim IS, Kim NJ, Han SM, Lim S. Kim KA, et al. Among authors: kim cj, kim nj, kim jw. Life Sci. 2004 Apr 16;74(22):2769-79. doi: 10.1016/j.lfs.2003.10.020. Life Sci. 2004. PMID: 15043991

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results